Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Fijnheer

Showing results (11-20 of 106) with videos related to

Pageof 11
Sort By:
The Annals of Thoracic Surgery|April 28, 2005
C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularizationBernard Lo, Rob Fijnheer, Arno P Nierich, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 18, 2005
Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literatureIneke Krabbendam, Arie Franx, Michiel L Bots, et al.
Ophthalmology|December 26, 2006
Anterior uveitis: a manifestation of graft-versus-host diseaseYmkje M Hettinga, Leo F Verdonck, Rob Fijnheer, et al.
American Journal of Ophthalmology|September 6, 2005
The effect of non-steroidal anti-inflammatory drugs on inflammatory cystoid macular edemaBram van Kooij, Joke De Boer, Ninette Ten Dam, et al.
Anesthesia and Analgesia|August 31, 2004
Activation of hemostasis after coronary artery bypass grafting with or without cardiopulmonary bypassBernard Lo, Rob Fijnheer, Domenico Castigliego, et al.
British Journal of Haematology|July 9, 2002
Factor V Leiden in central venous catheter-associated thrombosisRob Fijnheer, Birgit Paijmans, Leo F Verdonck, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|September 3, 2002
Semicarbazide-sensitive amine oxidase in pre-eclampsia: no relation with markers of endothelial cell activationJ Marko Sikkema, Arie Franx, Rob Fijnheer, et al.
Blood|December 25, 2009
An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWFWouter Pos, James T B Crawley, Rob Fijnheer, et al.
Seminars in Thrombosis and Hemostasis|November 24, 2015
Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13Claudia Tersteeg, Rob Fijnheer, Gerard Pasterkamp, et al.
Blood|July 15, 2005
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2BJanine J J Hulstein, Philip G de Groot, Karen Silence, et al.
Pageof 11

Showing results (11-20 of 106) with videos related to

Sort By:
Pageof 11
The Annals of Thoracic Surgery|April 28, 2005
C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularizationBernard Lo, Rob Fijnheer, Arno P Nierich, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 18, 2005
Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literatureIneke Krabbendam, Arie Franx, Michiel L Bots, et al.
Ophthalmology|December 26, 2006
Anterior uveitis: a manifestation of graft-versus-host diseaseYmkje M Hettinga, Leo F Verdonck, Rob Fijnheer, et al.
American Journal of Ophthalmology|September 6, 2005
The effect of non-steroidal anti-inflammatory drugs on inflammatory cystoid macular edemaBram van Kooij, Joke De Boer, Ninette Ten Dam, et al.
Anesthesia and Analgesia|August 31, 2004
Activation of hemostasis after coronary artery bypass grafting with or without cardiopulmonary bypassBernard Lo, Rob Fijnheer, Domenico Castigliego, et al.
British Journal of Haematology|July 9, 2002
Factor V Leiden in central venous catheter-associated thrombosisRob Fijnheer, Birgit Paijmans, Leo F Verdonck, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|September 3, 2002
Semicarbazide-sensitive amine oxidase in pre-eclampsia: no relation with markers of endothelial cell activationJ Marko Sikkema, Arie Franx, Rob Fijnheer, et al.
Blood|December 25, 2009
An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWFWouter Pos, James T B Crawley, Rob Fijnheer, et al.
Seminars in Thrombosis and Hemostasis|November 24, 2015
Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13Claudia Tersteeg, Rob Fijnheer, Gerard Pasterkamp, et al.
Blood|July 15, 2005
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2BJanine J J Hulstein, Philip G de Groot, Karen Silence, et al.
Pageof 11